Bristol-Myers Squibb Co

Insider buying at BMS signals confidence: EVP Shanahan accumulates shares at a discount near a 52‑week high, boosting long‑term upside for investors.

Insider buying of BMS deferred units signals long‑term confidence, boosting shares toward their 52‑week high and supporting the company’s drug‑pipeline outlook.

Insider buying surge at Bristol‑Myers Squibb signals confidence ahead of key product launches, suggesting a potential upside despite a flat share price.